Parallel Advisors, LLC Immuno Gen, Inc. Transaction History

Parallel Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$12.46 - $29.95 $10,566 - $25,397	848 Added 3028.57%	876 $25,000
Q2 2023 May 20, 2024	SELL	$3.75 - $20.05 $262 - $1,403	-70 Reduced 71.43%	28 $0
Q2 2023 Aug 04, 2023	SELL	$3.75 - $20.05 $262 - $1,403	-70 Reduced 71.43%	28 $0
Q1 2023 May 20, 2024	BUY	$3.67 - $4.92 $359 - $482	98 New	98 $0
Q1 2023 Apr 25, 2023	BUY	$3.67 - $4.92 $359 - $482	98 New	98 $0
Q1 2022 Apr 28, 2022	SELL	$4.26 - $7.48 $157 - $276	-37 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$4.75 - $7.5 $175 - $277	37 New	37 $0
Q1 2019 May 01, 2019	SELL	$2.41 - $5.91 $1,209 - $2,966	-502 Closed	0 $0
Q2 2018 Jul 30, 2018	BUY	$9.52 - $12.15 $4,779 - $6,099	502 New	502 $4,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.